Novo Nordisk Achieves 27.7% Weight Loss in Early Responders with Semaglutide 7.2 mg in STEP UP Trial

Novo Nordisk's STEP UP data, presented at the European Congress on Obesity (ECO) in Istanbul this week, signal a near-term formulation and supply challenge: a higher-dose semaglutide 7.2 mg presentation that outperforms the approved 2.4 mg dose will require manufacturers and CMOs to revisit fill-finish capacity, device compatibility, and cold-chain infrastructure before any commercial scale-up can follow a potential regulatory submission.

The sub-analysis, drawn from a 1,400-participant, 72-week trial comparing semaglutide 7.2 mg, 2.4 mg, and placebo in adults with obesity and without type 2 diabetes, identified "early responders" as participants achieving 15% or more body weight reduction within 24 weeks. Approximately 27% of participants on the 7.2 mg dose met that threshold, versus 21% on 2.4 mg and 3% on placebo. That early-responder cohort reached a mean weight loss of 27.7% at week 72 on the higher dose, compared with 24.8% on 2.4 mg. Across the full trial population, the 7.2 mg dose produced 20.7% mean weight loss against 17.5% for the 2.4 mg arm, with a safety and tolerability profile described as consistent between doses.

A separate MRI-based sub-analysis of 55 participants found that 84% of total weight lost with semaglutide (both doses combined) was attributable to fat mass reduction, with abdominal visceral fat declining by more than 30%. Muscle mass decreased by only 10% from baseline, accompanied by measurable improvement in intramuscular fat content. For QA and regulatory leads, the body-composition data add a secondary endpoint dimension that could shape labeling negotiations with EMA and FDA if Novo Nordisk pursues a supplemental or new drug application for the 7.2 mg dose.

The supply-chain read is direct: a higher-dose formulation in the same auto-injector platform used for Wegovy 2.4 mg would require device validation studies under 21 CFR Part 211 and ICH Q10 quality system frameworks to confirm dose accuracy and container-closure integrity at the new concentration. Fill-finish lines already operating near capacity for the existing semaglutide portfolio would face additional qualification burdens, particularly if the 7.2 mg presentation demands a reformulated excipient profile or altered viscosity specifications. Cold-chain parameters, currently aligned to the 2.4 mg product, would need equivalence data before distribution networks could be extended without revalidation.

Novo Nordisk has not disclosed a regulatory submission timeline for semaglutide 7.2 mg, meaning plant heads and supply-chain leads have a finite window to assess capacity gaps and initiate process validation planning before demand signals from early-responder patient segments accelerate.

Source: Novo Nordisk A/S via GlobeNewswire, 12 May 2026.